ESMO 2022 journaal | Longcarcinoom

Prof. dr. Egbert Smit en dr. Lizza Hendriks waren bij ons te gast in de studio in Parijs om het belangrijkste ESMO-nieuws op het gebied van longcarcinoom door te nemen.

Bent u vooral geïnteresseerd in een specifiek onderwerp? Maak dan gebruik van onze hoofdstukindeling. Deze is te herkennen aan de drie streepjes rechtsonder in de videospeler.

De volgende abstracts komen in dit journaal ter sprake:

Rol van circulerend tumor DNA

• Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer
• Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

EGFR-resistentie en KRAS-mutaties

• ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
• Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
• Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutant Metastatic Non–Small Cell Lung Cancer (NSCLC): Interim Results From the Phase 2 DESTINY-Lung02 Trial
• Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

Immunotherapie bij NSCLC

• KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
• 5-Year Update From KEYNOTE-407: Pembrolizumab Plus Chemotherapy in Squamous Non‒Small-Cell Lung Cancer (NSCLC)
• IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
• Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial
• Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable lung cancer: the INCREASE trial

Oorzaak & preventie longkanker

• Mechanism of Action and an Actionable Inflammatory Axis for Air Pollution Induced Non-Small Cell Lung Cancer: Towards Molecular Cancer Prevention

Bekijk hier het volledige overzicht van onze ESMO 2022 journaals en interviews.

Wij zijn benieuwd wat u van dit programma vindt en stellen het op prijs als u het evaluatieformulier invult. Gemiddeld duurt het 2 minuten om de enquête te vullen.